Physician profile
Thomas Wells
NPI 1386006575
$6,589.57
in general payments reported to CMS, 2019-2025
28 companies · $2,183 in 2025
The $2,183 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $956 · 2024: $3,451 · 2025: $2,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,812 · Travel and Lodging: $1,759 · Education: $18.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,812.09 |
| Travel and Lodging | $1,758.61 |
| Education | $18.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,888.42 | 2023-2025 | Rinvoq, Skyrizi, Linzess |
| Intuitive Surgical, INC. | $1,758.61 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $515.42 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Regeneron Healthcare Solutions, INC. | $320.50 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $273.33 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $246.10 | 2023-2025 | |
| Genzyme Corporation | $222.34 | 2023-2025 | |
| Janssen Biotech, INC. | $209.02 | 2023-2025 | Tremfya, Stelara, Remicade |
| Ardelyx, INC. | $179.33 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $154.24 | 2023-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $123.26 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $122.75 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $95.70 | 2023-2024 | Linzess |
| Pfizer INC. | $93.36 | 2025 | |
| Lilly USA, LLC | $81.03 | 2024-2025 | Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $66.75 | 2024 | |
| Braintree Laboratories, INC. | $41.64 | 2025 | Suflave |
| Daiichi Sankyo INC. | $37.22 | 2025 | Injectafer |
| Intercept Pharmaceuticals, INC. | $24.77 | 2025 | |
| Medtronic, INC. | $19.92 | 2023 | Endoflip |
| Celltrion USA INC. | $18.87 | 2024 | Zymfentra |
| Alnylam Pharmaceuticals INC. | $16.55 | 2024 | Givlaari |
| Capsovision, INC. | $15.75 | 2023 | Capsocam Plus |
| Astrazeneca Pharmaceuticals Lp | $13.97 | 2023 | Andexxa |
| Madrigal Pharmaceuticals | $13.82 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $13.46 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $13.30 | 2023 | Dificid |
| Organon LLC | $10.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.